Intra-tumoral application of a heregulin-exotoxin-A fusion protein causes rapid tumor regression without adverse systemic or local effects

International Journal of Cancer

Volumn 70, Issue 6, 1997, Pages 682-687

  Groner, Bernd ^a   Wick, Bettina ^a   Jeschke, Margit ^b   Fiebig, Heinz Herbert ^c   Dengler, Wolfgang ^c   Runau, Tatiana ^c   Mihatsch, Michael ^d   Kahl, Ralf ^a   Schmidt, Mathias ^a   Wels, Winfried ^a   Stöcklin, Elisabeth ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b CIBA GEIGY LTD   (Switzerland)

^c CHARLES RIVER LABORATORIES   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EXOTOXIN; HEREGULIN ENTOTOXIN A FUSION PROTEIN; HYBRID PROTEIN; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; INTRACARDIAC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; LIVER NECROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; EXOTOXINS; FEMALE; GLYCOPROTEINS; LIVER; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEUREGULIN-1; RATS; RECOMBINANT FUSION PROTEINS;

EID: 0030888743     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970317)70:6<682::AID-IJC10>3.0.CO;2-C     Document Type: Article

References (25)

1. ALTIOK, N., BESSEREAU, J.-L. and CHANCEUX, J.-P., ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine-receptor gene expression in muscle: differential expression at the endplate. EMBO J., 14, 4258-4266 (1995).
2. BARBACCI, E.G., GUARINO, B.C., STROH, J.G., SINGLETON, D.H., ROSNACK, K.J., MOVER, J.D. and ANDREWS, G.C., The structural basis for the specificity of epidermal growth factor and heregulin binding. J. biol. Chem., 270, 9585-9589 (1995).
3. BRINKMANN, U. and PASTAN, I., Immunotoxins against cancer. Biochim biophys. Acta, 1198, 27-45 (1994).
4. CARRAWAY III, K.L., Involvement of the neuregulins and their receptors in cardiac and neural development. BioEssays, 18, 263-266 (1996).
5. FIDDES, R.J., JANES, P.W., SANDERSON, G.M., SIVERTSEN, S.P., SUTHERLAND, R.L. and DALY, R.J., Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast-cancer cells. Cell Growth Diff., 6, 1567-1577 (1995).
6. FRANCISCO, J.A., GILLILAND, L.K., STEBBINS, M.R., NORRIS, N.A., LEDBETTER, J.A. and SIEGALL, C.B., Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res., 55, 3099-3104 (1995).
7. FRANKEL, A.E., FITZGERALD, D., SIEGALL, C. and PRESS, O.W., Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins. Cancer Res., 56, 926-932 (1996).
8. GHETIE, M.-A. and VITETTA, E.S., Recent developments in immunotoxin therapy. Curr. Opin. Immunol., 6, 707-714 (1994).
9. GOLDBERG, M.R. and 12 OTHERS, Phase-I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res., 1, 57-61 (1995).
10. HAUGEN, D.R.F., AKSLEN, L.A., VARHAUG, J.E. and LILLEHAUG, J.R., Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res., 56, 1184-1188 (1996).
11. HYNES, N.E. and GRONER, B., A target for tumour-directed therapy. Nature Medicine, 1, 631-632 (1995).
12. JESCHKE, M., WELS, W., DENGLER, W., IMBER, R., STÖCKLIN, E. and GRONER, B., Targeted inhibition of tumor-cell growth by recombinant heregulintoxin fusion proteins. Int. J. Cancer, 60, 730-739 (1995).
13. KARUNAGARAN, D., TZAHAR, E., BEERLI, R.R., CHEN, X., GRAUS-PORTA, D., RATZKIN, B.J., SEGER, R., HYNES, N.E. and YARDEN, Y., ErbB-2 is a common auxiliary sub-unit of NDF and EGF receptors: implications for breast cancer. EMBO J., 15, 254-264 (1996).
14. KIHARA, A. and PASTAN, I., Cytotoxic activity of chimeric toxins containing the epidermal-growth-factor-like domain of heregulin fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res., 55, 71-77 (1995).
15. LEWIS, G.D., LOFGREN, J.A., McMURTREY, A.E., NUIJENS, A., FENDLY, B.M., BAUER, K.D. and SLIWKOWSKI, M.X., Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56, 1457-1465 (1996).
16. PAL L.H., GALLO, M.G., FITZGERALD, D.H. and PASTAN, I., Anti-tumor activity of a transforming growth factor α-Pseudomonas-exotoxin fusion protein (TGFa-PE40). Cancer Res., 51, 2808-2812 (1991).
17. PASTAN, I.H., ARCHER, G.E., McLENDON, R.E., FRIEDMAN, H.S., FUCHS, H.E., WANG, Q.-C., PAL L.H., HERNDON, J. and BIGNER, D.D., Intra-thecal administration of single-chain immunotoxin, LMB-7 (B3(Fv)-PE 38), produces cures of carcinomatous meningitis in a rat model. Proc. nat. Acad. Sci. (Wash.), 92, 2765-2769 (1995).
18. PELES, E. and YARDEN. Y., neu and its ligands: from an oncogene to neural factors. BioEssays, 15, 815-824 (1993).
19. SCHMIDT, M., HYNES, N.E., GRONER, B. and WELS, W., A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int. J. Cancer, 65, 538-546 (1996).
20. SIEGALL, C.B., Targeted toxins as anti-cancer agents. Cancer, 74, 1006-1012 (1994).
21. SIEGALL, C.B., BACUS, S.S., COHEN, B.D., PLOWMAN, G.D., MIXAN, B., CHACE, D., CHIN, D.M., GOETZE, A., GREEN, J.M., HELLSTROM, I., HELL-STROM, K.E. and FELL, H.P., HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J. biol. Chem., 270, 7625-7630 (1995).
22. WALLASCH, C., WEI, F.U., NIEDERFELLNER, G., JALLAL, B., ISSING, W. and ULLRICH, A., Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J., 14, 4267-4275 (1995).
23. erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int. J. Cancer, 60, 137-144 (1995a).
24. WELS, W., HARWERTH, I.-M., MÜLLER, M., GRONER, B. and HYNES, N.E., Selective inhibition of tumor-cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res., 52, 6310-6317 (1992).
25. WELS, W., MORITZ, D., SCHMIDT, M., JESCHKE, M., HYNES, N.E. and GRONER, B., Biotechnological and gene-therapeutic strategies in cancer treatment. Gene, 159, 73-80 (1995b).